[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Amphetamine is combined with Antipyrine.]
[J01GA01, streptomycin, Amphetamine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Amphetamine may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Amphetamine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Amphetamine may decrease the excretion rate of Sulfadiazine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Amphetamine may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Amphetamine is combined with Sulindac.]
[N05AL01, sulpiride, Sulpiride may decrease the stimulatory activities of Amphetamine.]
[N03AX03, sulthiame, The therapeutic efficacy of Sulthiame can be decreased when used in combination with Amphetamine.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Amphetamine is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Amphetamine.]
[N05CD07, temazepam, Amphetamine may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Amphetamine is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, Amphetamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Amphetamine may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Amphetamine.]
[S03AA02, tetracycline, Amphetamine may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N05AE05, lurasidone, The therapeutic efficacy of Lurasidone can be decreased when used in combination with Amphetamine.]
[A04AD10, dronabinol, The metabolism of Amphetamine can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Apomorphine.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Theobromine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Amphetamine.]
[P02CA02, thiabendazole, Amphetamine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the stimulatory activities of Amphetamine.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be decreased when used in combination with Amphetamine.]
[N05AB08, thioproperazine, The therapeutic efficacy of Thioproperazine can be decreased when used in combination with Amphetamine.]
[N05AC02, thioridazine, The therapeutic efficacy of Thioridazine can be decreased when used in combination with Amphetamine.]
[N05AF04, thiothixene, Thiothixene may decrease the stimulatory activities of Amphetamine.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Amphetamine.]
[G04BE06, moxisylyte, The therapeutic efficacy of Moxisylyte can be decreased when used in combination with Amphetamine.]
[V04CJ01, thyrotropin, The risk or severity of adverse effects can be increased when Amphetamine is combined with Thyrotropin.]
[V04CJ02, thyrotropin-releasing hormone, The risk or severity of adverse effects can be increased when Amphetamine is combined with Protirelin.]
[N05AL03, tiapride, Tiapride may decrease the stimulatory activities of Amphetamine.]
[B01AC05, ticlopidine, The metabolism of Amphetamine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, Amphetamine may increase the analgesic activities of Tilidine.]
[S01ED01, timolol, The therapeutic efficacy of Timolol can be decreased when used in combination with Amphetamine.]
[P01AB02, tinidazole, Amphetamine may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Amphetamine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Amphetamine may decrease the excretion rate of Tolazamide which could result in a higher serum level.]
[M02AX02, tolazoline, The therapeutic efficacy of Tolazoline can be decreased when used in combination with Amphetamine.]
[V04CA01, tolbutamide, Amphetamine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Amphetamine is combined with Tolmetin.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypertensive activities of Amphetamine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Amphetamine.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Amphetamine.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Amphetamine may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Mepenzolate.]
[A16AX12, trientine, Amphetamine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Amphetamine.]
[S01AD02, trifluridine, Amphetamine may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[N05AD02, trifluperidol, Trifluperidol may decrease the stimulatory activities of Amphetamine.]
[N05AA05, triflupromazine, Triflupromazine may decrease the stimulatory activities of Amphetamine.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Trihexyphenidyl.]
[A03AA05, trimebutine, Amphetamine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[R06AD01, trimeprazine, Amphetamine may decrease the sedative and stimulatory activities of Alimemazine.]
[N03AC02, trimethadione, The therapeutic efficacy of Trimethadione can be decreased when used in combination with Amphetamine.]
[C02BA01, trimethaphan, Amphetamine may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Amphetamine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AA06, trimipramine, Amphetamine may decrease the sedative and stimulatory activities of Trimipramine.]
[R06AC04, tripelennamine, Amphetamine may decrease the sedative and stimulatory activities of Tripelennamine.]
[R06AX07, triprolidine, Amphetamine may decrease the sedative and stimulatory activities of Triprolidine.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Amphetamine can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of serotonin syndrome can be increased when Tryptophan is combined with Amphetamine.]
[C09CA09, azilsartan medoxomil, Amphetamine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[R03DX07, roflumilast, Amphetamine may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Amphetamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Amphetamine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Amphetamine can be decreased when combined with Abiraterone.]
[J05AG05, rilpivirine, The metabolism of Amphetamine can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Amphetamine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The therapeutic efficacy of Ezogabine can be decreased when used in combination with Amphetamine.]
[B01AF01, rivaroxaban, Amphetamine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Indacaterol.]
[C08DA01, verapamil, The therapeutic efficacy of Verapamil can be decreased when used in combination with Amphetamine.]
[N06AX09, viloxazine, The metabolism of Amphetamine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Amphetamine can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Amphetamine may decrease the antihypertensive activities of Vincamine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[B01AA03, warfarin, Amphetamine may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Amphetamine can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Amphetamine is combined with Xenon.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Amphetamine.]
[N05AF05, zuclopenthixol, Amphetamine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[N03AX14, levetiracetam, The therapeutic efficacy of Levetiracetam can be decreased when used in combination with Amphetamine.]
[L01EC01, vemurafenib, The metabolism of Amphetamine can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M05BA05, tiludronic acid, Amphetamine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Amphetamine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[A02BC04, rabeprazole, Rabeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[S01XA15, ascorbic acid, The serum concentration of Amphetamine can be decreased when it is combined with Ascorbic acid.]
[N05AE04, ziprasidone, Amphetamine may decrease the sedative and stimulatory activities of Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Amphetamine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Amphetamine is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Amphetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Amphetamine may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Amphetamine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The therapeutic efficacy of Atenolol can be decreased when used in combination with Amphetamine.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Amphetamine is combined with Atropine.]
[M01CB03, auranofin, Amphetamine may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[B03XA04, peginesatide, Amphetamine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Amphetamine may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Amphetamine may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Amphetamine may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Amphetamine may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[A08AA11, lorcaserin, The metabolism of Amphetamine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Amphetamine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Amphetamine can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, Amphetamine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[A02AA05, magnesium silicate, The serum concentration of Amphetamine can be increased when it is combined with Magnesium silicate.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Octopamine.]
[A02AC02, calcium silicate, The serum concentration of Amphetamine can be increased when it is combined with Calcium silicate.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be decreased when used in combination with Amphetamine.]
[D02BA02, octinoxate, Amphetamine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[N04BD02, rasagiline, Rasagiline may increase the hypertensive activities of Amphetamine.]
[C08CA13, lercanidipine, Amphetamine may decrease the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Mosapride.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Amphetamine.]
[N03AX22, perampanel, The therapeutic efficacy of Perampanel can be decreased when used in combination with Amphetamine.]
[N02CC03, zolmitriptan, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Amphetamine may decrease the sedative and stimulatory activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Amphetamine can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Amphetamine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Amphetamine is combined with Diethyl ether.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Amphetamine.]
[V08CA11, gadofosveset, Amphetamine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Amphetamine.]
[A16AX08, teduglutide, Amphetamine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Amphetamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Amphetamine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Amphetamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[G03XC05, ospemifene, The metabolism of Amphetamine can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Amphetamine is combined with Benorilate.]
[N05AD07, benperidol, Benperidol may decrease the stimulatory activities of Amphetamine.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX06, tegaserod, The metabolism of Amphetamine can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The risk or severity of adverse effects can be increased when Amphetamine is combined with Tiratricol.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Amphetamine.]
[L03AA12, ancestim, Amphetamine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Amphetamine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Amphetamine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Amphetamine may decrease the sedative and stimulatory activities of Benzatropine.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Benzydamine.]
[L01EE01, trametinib, Amphetamine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Amphetamine.]
[H05AA03, parathyroid hormone, The risk or severity of adverse effects can be increased when Amphetamine is combined with Parathyroid hormone.]
[V09AX05, florbetapir F-18, Amphetamine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Levomilnacipran.]
[C08EA02, bepridil, The metabolism of Amphetamine can be decreased when combined with Bepridil.]
[C02KX05, riociguat, Amphetamine may decrease the antihypertensive activities of Riociguat.]
[A10BJ03, lixisenatide, Amphetamine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Amphetamine may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Amphetamine.]
[N06AX26, vortioxetine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Vortioxetine.]
[G03AC08, etonogestrel, Amphetamine may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The therapeutic efficacy of Eslicarbazepine can be decreased when used in combination with Amphetamine.]
[J05AP08, sofosbuvir, Amphetamine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The therapeutic efficacy of Vigabatrin can be decreased when used in combination with Amphetamine.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, The therapeutic efficacy of Amphetamine can be increased when used in combination with Droxidopa.]
[C07AB04, acebutolol, The therapeutic efficacy of Acebutolol can be decreased when used in combination with Amphetamine.]
[N05CH03, tasimelteon, Amphetamine may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, The metabolism of Amphetamine can be increased when combined with Apremilast.]
[L02BG02, formestane, Amphetamine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[N07CA01, betahistine, Amphetamine may decrease the sedative and stimulatory activities of Betahistine.]
[S01ED02, betaxolol, The therapeutic efficacy of Betaxolol can be decreased when used in combination with Amphetamine.]
[V03AB34, fomepizole, Amphetamine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Amphetamine may decrease the antihypertensive activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Amphetamine can be increased when combined with Siltuximab.]
[A03BA03, hyoscyamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Hyoscyamine.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Amphetamine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[D11AA01, glycopyrronium, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Glycopyrronium.]
[V08AA04, iothalamic acid, Amphetamine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[A16AX10, eliglustat, The metabolism of Amphetamine can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Amphetamine can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N05AA04, acepromazine, The therapeutic efficacy of Acepromazine can be decreased when used in combination with Amphetamine.]
[A06AH03, naloxegol, Amphetamine may increase the analgesic activities of Naloxegol.]
[N04AA02, biperiden, The metabolism of Amphetamine can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Amphetamine.]
[S03AA06, gentamicin, Amphetamine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Amphetamine.]
[B01AF03, edoxaban, Amphetamine may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Amphetamine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Amphetamine can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Amphetamine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Amphetamine may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Amphetamine may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Difemerine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Amphetamine can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, Amphetamine may increase the analgesic activities of Eluxadoline.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Amphetamine.]
[A04AD14, rolapitant, The metabolism of Amphetamine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The serum concentration of Amphetamine can be increased when it is combined with Magnesium peroxide.]
[N05AX15, cariprazine, Cariprazine may decrease the stimulatory activities of Amphetamine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Amphetamine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Amphetamine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N05AB07, acetophenazine, Acetophenazine may decrease the stimulatory activities of Amphetamine.]
[A02BC03, lansoprazole, Lansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[V03AB37, idarucizumab, Amphetamine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Amphetamine.]
[J02AC05, isavuconazole, The metabolism of Amphetamine can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Amphetamine.]
[L01XG03, ixazomib, Amphetamine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Amphetamine may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, The therapeutic efficacy of Alfuzosin can be decreased when used in combination with Amphetamine.]
[M04AB05, lesinurad, Amphetamine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Amphetamine is combined with Alminoprofen.]
[A02AB06, aloglutamol, The serum concentration of Amphetamine can be increased when it is combined with Aloglutamol.]
[N03AX23, brivaracetam, The therapeutic efficacy of Brivaracetam can be decreased when used in combination with Amphetamine.]
[N05BA08, bromazepam, Amphetamine may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amphetamine.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Amphetamine can be increased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, The serum concentration of Amphetamine can be increased when it is combined with Aluminium phosphate.]
[R06AB01, brompheniramine, Amphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.]
[N06AA19, amineptin, The therapeutic efficacy of Amineptine can be increased when used in combination with Amphetamine.]
[C08CA01, amlodipine, Amphetamine may decrease the antihypertensive activities of Amlodipine.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, Amphetamine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, The therapeutic efficacy of Bupranolol can be decreased when used in combination with Amphetamine.]
[N07BC01, buprenorphine, Amphetamine may increase the analgesic activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Buspirone.]
[L01XX27, arsenic trioxide, Amphetamine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA03, clofezone, Rabeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N02AF01, butorphanol, Amphetamine may increase the analgesic activities of Butorphanol.]
[R06AX09, azatadine, Amphetamine may decrease the sedative and stimulatory activities of Azatadine.]
[S01GX07, azelastine, Amphetamine may decrease the sedative and stimulatory activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Amphetamine can be decreased when combined with Rucaparib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Amphetamine is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Bambuterol.]
[R03DA08, bamifylline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Bamifylline.]
[A06AH05, naldemedine, Amphetamine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Amphetamine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Pregabalin can be decreased when used in combination with Amphetamine.]
[N03AX30, beclamide, The therapeutic efficacy of Beclamide can be decreased when used in combination with Amphetamine.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Caffeine.]
[C09AA07, benazepril, Amphetamine may decrease the antihypertensive activities of Benazepril.]
[A12AA04, calcium carbonate, The serum concentration of Amphetamine can be increased when it is combined with Calcium carbonate.]
[P01CA02, benznidazole, Amphetamine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Linezolid is combined with Amphetamine.]
[J05AF06, abacavir, Amphetamine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Amphetamine can be decreased when combined with Tipranavir.]
[H03BA03, benzylthiouracil, The risk or severity of adverse effects can be increased when Amphetamine is combined with Benzylthiouracil.]
[N07XX13, valbenazine, Amphetamine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Amphetamine can be increased when combined with Infliximab.]
[H05AA04, abaloparatide, The risk or severity of adverse effects can be increased when Amphetamine is combined with Abaloparatide.]
[N04BD03, safinamide, Safinamide may increase the hypertensive activities of Amphetamine.]
[J01MA23, delafloxacin, Amphetamine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, Amphetamine may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Amphetamine.]
[A02BX12, bismuth subnitrate, The serum concentration of Amphetamine can be increased when it is combined with Bismuth subnitrate.]
[C07AB07, bisoprolol, The therapeutic efficacy of Bisoprolol can be decreased when used in combination with Amphetamine.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Bitolterol.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C07AA17, bopindolol, The therapeutic efficacy of Bopindolol can be decreased when used in combination with Amphetamine.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Bornaprine.]
[N05AD06, bromperidol, Bromperidol may decrease the stimulatory activities of Amphetamine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Amphetamine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The therapeutic efficacy of Buflomedil can be decreased when used in combination with Amphetamine.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Amphetamine is combined with Bumadizone.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Amphetamine.]
[N06AA15, butriptyline, Amphetamine may decrease the sedative and stimulatory activities of Butriptyline.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AX18, acrivastine, Amphetamine may decrease the sedative and stimulatory activities of Acrivastine.]
[C09AA01, captopril, Amphetamine may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, Amphetamine may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Amphetamine may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Camylofin.]
[H03BB01, carbimazole, The risk or severity of adverse effects can be increased when Amphetamine is combined with Carbimazole.]
[R06AA08, carbinoxamine, Amphetamine may decrease the sedative and stimulatory activities of Carbinoxamine.]
[C07AG02, carvedilol, The therapeutic efficacy of Carvedilol can be decreased when used in combination with Amphetamine.]
[N03AX24, cannabidiol, The metabolism of Amphetamine can be decreased when combined with Cannabidiol.]
[L04AA37, baricitinib, Amphetamine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Amphetamine.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01GB14, plazomicin, Amphetamine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Celiprolol can be decreased when used in combination with Amphetamine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Amphetamine.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Amphetamine.]
[A16AX14, migalastat, Amphetamine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Amphetamine can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Amphetamine.]
[S01GX12, cetirizine, Amphetamine may decrease the sedative and stimulatory activities of Cetirizine.]
[R06AC03, chloropyramine, Amphetamine may decrease the sedative and stimulatory activities of Chloropyramine.]
[D08AE05, chloroxylenol, Amphetamine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Amphetamine may decrease the sedative and stimulatory activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Amphetamine is combined with Lornoxicam.]
[R03DA02, oxtriphylline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Oxtriphylline.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Amphetamine.]
[L04AA39, emapalumab, The metabolism of Amphetamine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Amphetamine may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Amphetamine is combined with Amifampridine.]
[A06AX05, prucalopride, Amphetamine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, Amphetamine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, Amphetamine may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[A03FA08, cinitapride, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Cinitapride.]
[A09AB04, citric acid, The excretion of Amphetamine can be decreased when combined with Citric acid.]
[P02BX04, triclabendazole, The metabolism of Amphetamine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Amphetamine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Amphetamine is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Amphetamine.]
[N06AX29, brexanolone, The therapeutic efficacy of Brexanolone can be decreased when used in combination with Amphetamine.]
[N05BA09, clobazam, The metabolism of Amphetamine can be decreased when combined with Clobazam.]
[R05DB10, chlophedianol, Amphetamine may decrease the sedative and stimulatory activities of Clofedanol.]
[C09CA06, candesartan, Amphetamine may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Amphetamine can be increased when combined with Etanercept.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N05AA06, cyamemazine, Cyamemazine may decrease the stimulatory activities of Amphetamine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Cyclobenzaprine.]
[L01EJ02, fedratinib, The metabolism of Amphetamine can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, Amphetamine may decrease the sedative and stimulatory activities of Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Amphetamine.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The therapeutic efficacy of Yohimbine can be decreased when used in combination with Amphetamine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Amphetamine.]
[N03AX25, cenobamate, The therapeutic efficacy of Cenobamate can be decreased when used in combination with Amphetamine.]
[A16AX16, givosiran, The serum concentration of Amphetamine can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Amphetamine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, Amphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, Amphetamine may decrease the sedative and stimulatory activities of Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Amphetamine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, Amphetamine may increase the analgesic activities of Dezocine.]
[N05AD10, lumateperone, Lumateperone may decrease the stimulatory activities of Amphetamine.]
[M01AX21, diacetylrhein, The metabolism of Amphetamine can be decreased when combined with Diacerein.]
[H02CA02, osilodrostat, The metabolism of Amphetamine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Amphetamine.]
[N02CC07, frovatriptan, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Frovatriptan.]
[G04CB02, dutasteride, The therapeutic efficacy of Dutasteride can be decreased when used in combination with Amphetamine.]
[R02AA03, dichlorobenzyl alcohol, Amphetamine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Amphetamine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02AA08, dihydrocodeine, Amphetamine may increase the analgesic activities of Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Eletriptan.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Amphetamine is combined with Rofecoxib.]
[C08CA16, clevidipine, Amphetamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The metabolism of Amphetamine can be decreased when combined with Dronedarone.]
[R06AA07, diphenylpyraline, Amphetamine may decrease the sedative and stimulatory activities of Diphenylpyraline.]
[N03AG02, dipropylacetamide, The therapeutic efficacy of Valpromide can be decreased when used in combination with Amphetamine.]
[R06AE04, chlorcyclizine, Amphetamine may decrease the sedative and stimulatory activities of Chlorcyclizine.]
[C02AA06, methoserpidine, Amphetamine may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Dopexamine.]
[G04BD09, trospium, The metabolism of Amphetamine can be decreased when combined with Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Amphetamine is combined with Droxicam.]
[V08CA05, mangafodipir, Amphetamine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Amphetamine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Amphetamine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The therapeutic efficacy of Clomethiazole can be decreased when used in combination with Amphetamine.]
[C08CA17, levamlodipine, Amphetamine may decrease the antihypertensive activities of Levamlodipine.]
[R06AX22, ebastine, Amphetamine may decrease the sedative and stimulatory activities of Ebastine.]
[P01BB01, proguanil, The metabolism of Amphetamine can be decreased when combined with Proguanil.]
[N02AX07, oliceridine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Amphetamine can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, Amphetamine may decrease the sedative and stimulatory activities of Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Amphetamine can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, Amphetamine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.]
[N05AF03, chlorprothixene, Amphetamine may decrease the sedative and stimulatory activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Amphetamine may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[A11CC05, cholecalciferol, The metabolism of Amphetamine can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Amphetamine is combined with Ethenzamide.]
[N02BA03, choline salicylate, Amphetamine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Amphetamine.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Amphetamine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Amphetamine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Amphetamine can be decreased when combined with Berotralstat.]
[M01AX25, chondroitin sulfates, Amphetamine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Amphetamine is combined with Naxitamab.]
[N03AX10, felbamate, The therapeutic efficacy of Felbamate can be decreased when used in combination with Amphetamine.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Amphetamine is combined with Fenbufen.]
[N06BA10, fenethylline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Fenethylline.]
[C01CA19, fenoldopam, Amphetamine may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Amphetamine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Amphetamine is combined with Finasteride.]
[J01DD15, cefdinir, Amphetamine may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Amphetamine may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[N02BG07, flupirtine, Amphetamine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Formoterol.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Amphetamine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Amphetamine can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Amphetamine may decrease the antihypertensive activities of Dasiglucagon.]
[G03GA06, follitropin beta, The risk or severity of adverse effects can be increased when Amphetamine is combined with Follitropin.]
[A02BA01, cimetidine, Amphetamine may decrease the sedative and stimulatory activities of Cimetidine.]
[N02BF01, gabapentin, The therapeutic efficacy of Gabapentin can be decreased when used in combination with Amphetamine.]
[V08CA04, gadoteridol, Amphetamine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, Amphetamine may decrease the sedative and stimulatory activities of Cinnarizine.]
[S03AA07, ciprofloxacin, Amphetamine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01XA01, cisplatin, Amphetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The metabolism of Amphetamine can be decreased when combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Amphetamine.]
[V09AB03, ioflupane I-123, Amphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.]
[V09AA01, technetium Tc 99m exametazime, Amphetamine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Amphetamine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, Amphetamine may decrease the sedative and stimulatory activities of Clemastine.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Amphetamine is combined with Mefenamic acid.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Amphetamine can be decreased when combined with Ropeginterferon alfa-2b.]
[N01BB10, levobupivacaine, Amphetamine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AA04, clomipramine, The therapeutic efficacy of Clomipramine can be increased when used in combination with Amphetamine.]
[N03AE01, clonazepam, The therapeutic efficacy of Clonazepam can be decreased when used in combination with Amphetamine.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Amphetamine.]
[J05AH02, oseltamivir, Amphetamine may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, Clothiapine may decrease the stimulatory activities of Amphetamine.]
[A04AA01, ondansetron, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Granisetron.]
[N05AH02, clozapine, Amphetamine may decrease the sedative and stimulatory activities of Clozapine.]
[J01GB12, arbekacin, Amphetamine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The metabolism of Amphetamine can be decreased when combined with Cocaine.]
[C02KB01, metyrosine, Amphetamine may decrease the antihypertensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Amphetamine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Amphetamine is combined with Proquazone.]
[R05DA04, codeine, Amphetamine may increase the analgesic activities of Codeine.]
[M04AC01, colchicine, Amphetamine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Homatropine methylbromide.]
[J01XB01, colistin, Amphetamine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[A02AD04, hydrotalcite, The serum concentration of Amphetamine can be increased when it is combined with Hydrotalcite.]
[N01AB07, desflurane, The risk or severity of hypertension can be increased when Amphetamine is combined with Desflurane.]
[A04AA03, tropisetron, Amphetamine may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Amphetamine.]
[A10BX03, nateglinide, Amphetamine may decrease the excretion rate of Nateglinide which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Amphetamine is combined with Imidazole salicylate.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Amphetamine.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Amphetamine is combined with Indobufen.]
[R06AX27, desloratadine, Amphetamine may decrease the sedative and stimulatory activities of Desloratadine.]
[J05AB14, valganciclovir, Amphetamine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Amphetamine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Amphetamine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Amphetamine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Amphetamine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Amphetamine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Amphetamine is combined with Valdecoxib.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Amphetamine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Amphetamine is combined with Parecoxib.]
[R06AD09, isothipendyl, Amphetamine may decrease the sedative and stimulatory activities of Isothipendyl.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[S01GX06, emedastine, Amphetamine may decrease the sedative and stimulatory activities of Emedastine.]
[N05BA10, ketazolam, Amphetamine may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Amphetamine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Amphetamine can be increased when it is combined with Imatinib.]
[A02BC05, esomeprazole, Esomeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[C08CA09, lacidipine, Amphetamine may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Amphetamine.]
[N07BC04, lofexidine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Amphetamine is combined with Lonazolac.]
[R06AX13, loratadine, Amphetamine may decrease the sedative and stimulatory activities of Loratadine.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Amphetamine is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C09AA03, lisinopril, Amphetamine may decrease the antihypertensive activities of Lisinopril.]
[A02AD02, magaldrate, The serum concentration of Amphetamine can be increased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, The serum concentration of Amphetamine can be increased when it is combined with Magnesium carbonate.]
[C08CA11, manidipine, The metabolism of Amphetamine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Amphetamine is combined with Mefenorex.]
[C07AA14, mepindolol, The therapeutic efficacy of Mepindolol can be decreased when used in combination with Amphetamine.]
[R06AD07, mequitazine, Amphetamine may decrease the sedative and stimulatory activities of Mequitazine.]
[J01DH02, meropenem, Amphetamine may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Adenosine.]
[R06AD04, methdilazine, Amphetamine may decrease the sedative and stimulatory activities of Methdilazine.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Amphetamine may decrease the sedative and stimulatory activities of Cyclizine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Melperone may decrease the stimulatory activities of Amphetamine.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Amphetamine.]
[N06AX07, minaprine, Minaprine may increase the hypertensive activities of Amphetamine.]
[S01XA18, cyclosporine, The metabolism of Amphetamine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypertensive activities of Amphetamine.]
[N06BA07, modafinil, The risk or severity of hypertension can be increased when Amphetamine is combined with Modafinil.]
[R06AX02, cyproheptadine, Amphetamine may decrease the sedative and stimulatory activities of Cyproheptadine.]
[C09AA13, moexipril, Amphetamine may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Amphetamine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Amphetamine is combined with Morniflumate.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC05, moxonidine, Amphetamine may decrease the antihypertensive activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Amphetamine is combined with Etoricoxib.]
[L01AX04, dacarbazine, Amphetamine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[C02CC04, debrisoquin, Amphetamine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of Tachycardia can be increased when Nabilone is combined with Amphetamine.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Amphetamine is combined with Nabumetone.]
[N07BB05, nalmefene, Amphetamine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The therapeutic efficacy of Nebivolol can be decreased when used in combination with Amphetamine.]
[S01GX04, nedocromil, Amphetamine may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The therapeutic efficacy of Nefazodone can be decreased when used in combination with Amphetamine.]
[C01DX16, nicorandil, Amphetamine may decrease the antihypertensive activities of Nicorandil.]
[L02BB02, nilutamide, Amphetamine may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[N03AG06, tiagabine, The therapeutic efficacy of Tiagabine can be decreased when used in combination with Amphetamine.]
[C01CA23, theodrenaline, The therapeutic efficacy of Amphetamine can be increased when used in combination with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Amphetamine is combined with Norfenefrine.]
[R05DA06, normethadone, Amphetamine may increase the analgesic activities of Normethadone.]
[B01AX05, fondaparinux, Amphetamine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Amphetamine is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Amphetamine is combined with Olsalazine.]
[N06AA01, desipramine, Amphetamine may decrease the sedative and stimulatory activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Amphetamine.]
[V04CH02, indigo carmine, Amphetamine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Amphetamine may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[C09XA02, aliskiren, Amphetamine may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Amphetamine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The therapeutic efficacy of Oxcarbazepine can be decreased when used in combination with Amphetamine.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Dexetimide.]
[G04BD04, oxybutynin, The metabolism of Amphetamine can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Amphetamine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Amphetamine can be decreased when combined with Gefitinib.]
[R05DA09, dextromethorphan, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Dextromethorphan.]
[N03AC01, paramethadione, The therapeutic efficacy of Paramethadione can be decreased when used in combination with Amphetamine.]
[N02AC01, dextromoramide, Amphetamine may increase the analgesic activities of Dextromoramide.]
[H05AA02, teriparatide, The risk or severity of adverse effects can be increased when Amphetamine is combined with Teriparatide.]
[N06AB05, paroxetine, The metabolism of Amphetamine can be decreased when combined with Paroxetine.]
[N07BC06, heroin, Amphetamine may increase the analgesic activities of Diamorphine.]
[C04AD01, pentifylline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Pentifylline.]
[P03AC04, permethrin, Amphetamine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The therapeutic efficacy of Diazepam can be decreased when used in combination with Amphetamine.]
[N03AX07, phenacemide, The therapeutic efficacy of Phenacemide can be decreased when used in combination with Amphetamine.]
[V03AH01, diazoxide, Amphetamine may decrease the antihypertensive activities of Diazoxide.]
[R06AX04, phenindamine, Amphetamine may decrease the sedative and stimulatory activities of Phenindamine.]
[N03AD02, phensuximide, The therapeutic efficacy of Phensuximide can be decreased when used in combination with Amphetamine.]
[N06AA08, dibenzepin, The therapeutic efficacy of Dibenzepin can be increased when used in combination with Amphetamine.]
[R05DA08, pholcodine, Amphetamine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Amphetamine is combined with Diclofenac.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[A03AA07, dicyclomine, Amphetamine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Amphetamine may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, Amphetamine may decrease the antihypertensive activities of Pinacidil.]
[N05AD05, pipamperone, Pipamperone may decrease the stimulatory activities of Amphetamine.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Amphetamine.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Pirbuterol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Diethylpropion.]
[C08CA03, isradipine, Amphetamine may decrease the antihypertensive activities of Isradipine.]
[D07XC04, diflucortolone, Amphetamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Amphetamine is combined with Diflunisal.]
[C01AA05, digoxin, Amphetamine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Amphetamine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The therapeutic efficacy of Dihydroergocristine can be decreased when used in combination with Amphetamine.]
[N02CA01, dihydroergotamine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Amphetamine.]
[N02AA03, hydromorphone, Amphetamine may increase the analgesic activities of Hydromorphone.]
[L04AX04, lenalidomide, Amphetamine may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[B01AC21, treprostinil, Amphetamine may decrease the antihypertensive activities of Treprostinil.]
[H03BC01, potassium perchlorate, The risk or severity of adverse effects can be increased when Amphetamine is combined with Potassium perchlorate.]
[V03AB04, pralidoxime, Amphetamine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[C08DB01, diltiazem, Amphetamine may decrease the antihypertensive activities of Diltiazem.]
[R06AA11, dimenhydrinate, Amphetamine may decrease the sedative and stimulatory activities of Dimenhydrinate.]
[V03AB09, dimercaprol, Amphetamine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R06AB03, dimethindene, Amphetamine may decrease the sedative and stimulatory activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Amphetamine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Amphetamine.]
[N06BC02, propentofylline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Propentofylline.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Amphetamine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Amphetamine is combined with Proglumetacin.]
[R03DA03, proxyphylline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Proxyphylline.]
[R06AA02, diphenhydramine, Amphetamine may decrease the sedative and stimulatory activities of Diphenhydramine.]
[A07DA01, diphenoxylate, Amphetamine may increase the analgesic activities of Diphenoxylate.]
[C09AA06, quinapril, Amphetamine may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The therapeutic efficacy of Quinupramine can be increased when used in combination with Amphetamine.]
[A03FA02, cisapride, The metabolism of Amphetamine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Amphetamine may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, Remoxipride may decrease the stimulatory activities of Amphetamine.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Reproterol.]
[S01AX06, resorcinol, Amphetamine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Amphetamine may decrease the excretion rate of Disopyramide which could result in a higher serum level.]
[P03AA04, disulfiram, The therapeutic efficacy of Amphetamine can be decreased when used in combination with Disulfiram.]
[N07XX02, riluzole, The therapeutic efficacy of Riluzole can be decreased when used in combination with Amphetamine.]
[N05AX08, risperidone, Amphetamine may decrease the sedative and stimulatory activities of Risperidone.]
[R06AE09, levocetirizine, Amphetamine may decrease the sedative and stimulatory activities of Levocetirizine.]
[N01BB09, ropivacaine, Amphetamine may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Amphetamine.]
[G04BE08, tadalafil, Amphetamine may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Amphetamine is combined with Ketorolac.]
[C02KX02, ambrisentan, Amphetamine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Amphetamine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Amphetamine is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The risk or severity of adverse effects can be increased when Amphetamine is combined with Salmon calcitonin.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Dobutamine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Amphetamine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Dopamine.]
[N06AA16, dothiepin, Amphetamine may decrease the sedative and stimulatory activities of Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Amphetamine is combined with Doxapram.]
[N06AA12, doxepin, Amphetamine may decrease the sedative and stimulatory activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Amphetamine can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Amphetamine may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[R06AA09, doxylamine, Amphetamine may decrease the sedative and stimulatory activities of Doxylamine.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of hypertension can be increased when Amphetamine is combined with Sevoflurane.]
[N05AD08, droperidol, The therapeutic efficacy of Droperidol can be decreased when used in combination with Amphetamine.]
[A08AA10, sibutramine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Amphetamine.]
[B05XA02, sodium bicarbonate, The serum concentration of Amphetamine can be increased when it is combined with Sodium bicarbonate.]
[V03AG05, sodium phosphate, The serum concentration of Amphetamine can be decreased when it is combined with Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, Amphetamine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Amphetamine may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Dyphylline.]
[N05AL02, sultopride, Sultopride may decrease the stimulatory activities of Amphetamine.]
[N02CC01, sumatriptan, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Sumatriptan.]
[V04CX07, edrophonium, Amphetamine may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The therapeutic efficacy of Talinolol can be decreased when used in combination with Amphetamine.]
[L01AX03, temozolomide, Amphetamine may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Amphetamine is combined with Tenoxicam.]
[G04CA03, terazosin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Amphetamine.]
[D01BA02, terbinafine, The metabolism of Amphetamine can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The therapeutic efficacy of Tertatolol can be decreased when used in combination with Amphetamine.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Amphetamine is combined with Tetryzoline.]
[N05AB05, thiopropazate, Thiopropazate may decrease the stimulatory activities of Amphetamine.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Emepronium.]
[N06AX14, tianeptine, The therapeutic efficacy of Tianeptine can be increased when used in combination with Amphetamine.]
[C09AA02, enalapril, Amphetamine may decrease the antihypertensive activities of Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Amphetamine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypertensive activities of Amphetamine.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Amphetamine.]
[N03AX11, topiramate, The therapeutic efficacy of Topiramate can be decreased when used in combination with Amphetamine.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Amphetamine is combined with Tramazoline.]
[C09AA10, trandolapril, Amphetamine may decrease the antihypertensive activities of Trandolapril.]
[N05CC01, chloral hydrate, Amphetamine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Tridihexethyl.]
[G03GA05, follitropin alfa, The risk or severity of adverse effects can be increased when Amphetamine is combined with Follitropin.]
[R06AX21, tritoqualine, Amphetamine may decrease the sedative and stimulatory activities of Tritoqualine.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Tulobuterol.]
[C02CA06, urapidil, The therapeutic efficacy of Urapidil can be decreased when used in combination with Amphetamine.]
[N05AL06, veralipride, Veralipride may decrease the stimulatory activities of Amphetamine.]
[L01CA04, vinorelbine, The metabolism of Amphetamine can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Amphetamine can be increased when used in combination with Ephedrine.]
[S01GX10, epinastine, Amphetamine may decrease the sedative and stimulatory activities of Epinastine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Amphetamine is combined with Xylometazoline.]
[S01EA01, epinephrine, The therapeutic efficacy of Amphetamine can be increased when used in combination with Epinephrine.]
[C09AA15, zofenopril, Amphetamine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Amphetamine.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Amphetamine is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N05AX11, zotepine, Zotepine may decrease the stimulatory activities of Amphetamine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C02AC02, guanfacine, Amphetamine may decrease the antihypertensive activities of Guanfacine.]
[C01BG01, moricizine, Moricizine may decrease the stimulatory activities of Amphetamine.]
[G02AB03, ergonovine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The therapeutic efficacy of Ergoloid mesylate can be decreased when used in combination with Amphetamine.]
[N02CA02, ergotamine, The therapeutic efficacy of Ergotamine can be decreased when used in combination with Amphetamine.]
[N03AG01, valproic acid, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Valproic acid.]
[L03AX05, pidotimod, Amphetamine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The therapeutic efficacy of Estazolam can be decreased when used in combination with Amphetamine.]
[A02BC02, pantoprazole, Pantoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[H05BX01, cinacalcet, The metabolism of Amphetamine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, Amphetamine may decrease the excretion rate of Estradiol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Amphetamine may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, Amphetamine may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Amphetamine.]
[V08CA03, gadodiamide, Amphetamine may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Gepefrine.]
[C01BD05, ibutilide, Amphetamine may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Amphetamine.]
[N03AD01, ethosuximide, Amphetamine can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be decreased when used in combination with Amphetamine.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Amphetamine is combined with Meloxicam.]
[S01XA06, ethylmorphine, Amphetamine may increase the analgesic activities of Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Amphetamine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Amphetamine is combined with Etomidate.]
[N05AE03, sertindole, Sertindole may decrease the stimulatory activities of Amphetamine.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[A02BA04, nizatidine, Amphetamine may decrease the sedative and stimulatory activities of Nizatidine.]
[R06AX11, astemizole, Amphetamine may decrease the sedative and stimulatory activities of Astemizole.]
[R06AX12, terfenadine, Amphetamine may decrease the sedative and stimulatory activities of Terfenadine.]
[P01AX07, trimetrexate, Amphetamine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Amphetamine.]
[N06AB08, fluvoxamine, The metabolism of Amphetamine can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Amphetamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Amphetamine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Amphetamine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Amphetamine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, Amphetamine may decrease the sedative and stimulatory activities of Famotidine.]
[A16AA01, levocarnitine, Amphetamine may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[C08CA02, felodipine, The metabolism of Amphetamine can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Amphetamine is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Fenoterol.]
[N02AB03, fentanyl, Amphetamine may increase the analgesic activities of Fentanyl.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Salbutamol.]
[B03AA10, ferrous ascorbate, The serum concentration of Amphetamine can be decreased when it is combined with Ferrous ascorbate.]
[L01BB06, clofarabine, Amphetamine may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, Amphetamine may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Amphetamine may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Amphetamine.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Amphetamine is combined with Floctafenine.]
[J02AC01, fluconazole, Amphetamine may decrease the excretion rate of Fluconazole which could result in a higher serum level.]
[J02AX01, flucytosine, Amphetamine may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Amphetamine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, Amphetamine may decrease the sedative and stimulatory activities of Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Amphetamine.]
[N06AA14, melitracen, The therapeutic efficacy of Melitracen can be increased when used in combination with Amphetamine.]
[L01BC09, floxuridine, Amphetamine may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Amphetamine.]
[N06AB03, fluoxetine, The serum concentration of Amphetamine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Flupentixol can be decreased when used in combination with Amphetamine.]
[N05AB02, fluphenazine, Fluphenazine may decrease the stimulatory activities of Amphetamine.]
[N05CD01, flurazepam, Amphetamine may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Amphetamine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, Fluspirilene may decrease the stimulatory activities of Amphetamine.]
[L02BB01, flutamide, Amphetamine may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[S02AA17, fosfomycin, Amphetamine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Amphetamine.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Amphetamine is combined with Adrafinil.]
[G01AX06, furazolidone, Furazolidone may increase the hypertensive activities of Amphetamine.]
[J05AE10, darunavir, The metabolism of Amphetamine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Amphetamine may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[N05AL05, amisulpride, Amisulpride may decrease the stimulatory activities of Amphetamine.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Amphetamine.]
[S01AD09, ganciclovir, Amphetamine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The therapeutic efficacy of Barbexaclone can be decreased when used in combination with Amphetamine.]
[N06AX08, bifemelane, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Bifemelane.]
[C10AB04, gemfibrozil, Amphetamine may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Amphetamine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Cabergoline.]
[C01CA21, cafedrine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Cafedrine.]
[N03AD03, methsuximide, The therapeutic efficacy of Methsuximide can be decreased when used in combination with Amphetamine.]
[N01AH02, alfentanil, Amphetamine may increase the analgesic activities of Alfentanil.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Amphetamine.]
[A10BB07, glipizide, Amphetamine may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The metabolism of Amphetamine can be decreased when combined with Dexmedetomidine.]
[C05AE01, nitroglycerin, Amphetamine may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, The therapeutic efficacy of Doxazosin can be decreased when used in combination with Amphetamine.]
[H01AB01, thyrotropin alfa, The risk or severity of adverse effects can be increased when Amphetamine is combined with Thyrotropin alfa.]
[L01EX02, sorafenib, Amphetamine may decrease the excretion rate of Sorafenib which could result in a higher serum level.]
[C07AB09, esmolol, The therapeutic efficacy of Esmolol can be decreased when used in combination with Amphetamine.]
[M01CB04, aurothioglucose, Amphetamine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Amphetamine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[N02CX05, fonazine, Amphetamine may decrease the sedative and stimulatory activities of Dimetotiazine.]
[C09AA09, fosinopril, Amphetamine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, The serum concentration of Amphetamine can be decreased when it is combined with Guanethidine.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Amphetamine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The therapeutic efficacy of Amphetamine can be decreased when used in combination with Haloperidol.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Amphetamine is combined with Halothane.]
[N05AH04, quetiapine, Amphetamine may decrease the sedative and stimulatory activities of Quetiapine.]
[N06BX13, idebenone, Amphetamine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[M04AA01, allopurinol, Amphetamine may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, Amphetamine may decrease the antihypertensive activities of Losartan.]
[G03DC01, allylestrenol, Amphetamine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Mesalazine.]
[C01CE02, milrinone, Amphetamine may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Amphetamine.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Amphetamine is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Amphetamine can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, Amphetamine may decrease the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Amphetamine is combined with Nimesulide.]
[R06AE06, oxatomide, Amphetamine may decrease the sedative and stimulatory activities of Oxatomide.]
[C09AA04, perindopril, Amphetamine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Amphetamine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Amphetamine.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Amphetamine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, The excretion of Amphetamine can be decreased when combined with Potassium citrate.]
[V03AB33, hydroxocobalamin, Amphetamine may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, The therapeutic efficacy of Propiverine can be decreased when used in combination with Amphetamine.]
[P01BA02, hydroxychloroquine, The metabolism of Amphetamine can be decreased when combined with Hydroxychloroquine.]
[N05AX07, prothipendyl, Prothipendyl may decrease the stimulatory activities of Amphetamine.]
[B05AA07, hetastarch, Amphetamine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Amphetamine may decrease the sedative and stimulatory activities of Hydroxyzine.]
[C02AC06, rilmenidine, Amphetamine may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Amphetamine is combined with Ibuprofen.]
[B05XA08, sodium acetate, Amphetamine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The excretion of Amphetamine can be decreased when combined with Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Amphetamine.]
[L01AA06, ifosfamide, Amphetamine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, Amphetamine may increase the analgesic activities of Sufentanil.]
[N06AA02, imipramine, Amphetamine may decrease the sedative and stimulatory activities of Imipramine.]
[R01AD07, tixocortol, Amphetamine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Amphetamine.]
[L01CE01, topotecan, Amphetamine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Amphetamine is combined with Indomethacin.]
[C02CA02, indoramin, The therapeutic efficacy of Indoramin can be decreased when used in combination with Amphetamine.]
[A11HA07, inositol, Amphetamine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Piperidolate.]
[S01XA28, varenicline, Amphetamine may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[A10BH01, sitagliptin, Amphetamine may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, Amphetamine may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Amphetamine may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[R06AE01, buclizine, Amphetamine may decrease the sedative and stimulatory activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Amphetamine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Anagrelide.]
[C07AA01, alprenolol, The therapeutic efficacy of Alprenolol can be decreased when used in combination with Amphetamine.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Amphetamine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The therapeutic efficacy of Iprindole can be increased when used in combination with Amphetamine.]
[N06AF05, iproniazid, Iproniazid may increase the hypertensive activities of Amphetamine.]
[N05AA07, chlorproethazine, Chlorproethazine may decrease the stimulatory activities of Amphetamine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypertensive activities of Amphetamine.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Amphetamine is combined with Isoetharine.]
[C09AA16, imidapril, Amphetamine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of hypertension can be increased when Amphetamine is combined with Isoflurane.]
[N04BX02, entacapone, The metabolism of Amphetamine can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Isoniazid.]
[J05AX05, inosine pranobex, Amphetamine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Amphetamine is combined with Isoprenaline.]
[C01DA14, isosorbide mononitrate, Amphetamine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, Amphetamine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Amphetamine is combined with Isoxsuprine.]
[N06AX18, reboxetine, The metabolism of Amphetamine can be decreased when combined with Reboxetine.]
[S01AA24, kanamycin, Amphetamine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[A02AB01, aluminum hydroxide, The serum concentration of Amphetamine can be increased when it is combined with Aluminum hydroxide.]
[L04AC07, tocilizumab, The metabolism of Amphetamine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Amphetamine may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Ketanserin.]
[B01AC22, prasugrel, Amphetamine may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Amphetamine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Amphetamine may decrease the sedative and stimulatory activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Amphetamine is combined with Ketoprofen.]
[L04AA24, abatacept, The metabolism of Amphetamine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, Amphetamine may decrease the sedative and stimulatory activities of Mizolastine.]
[S01GX08, ketotifen, Amphetamine may decrease the sedative and stimulatory activities of Ketotifen.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Arbutamine.]
[N04BC09, rotigotine, The metabolism of Amphetamine can be decreased when combined with Rotigotine.]
[D10AX03, azelaic acid, Amphetamine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Amphetamine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Labetalol can be decreased when used in combination with Amphetamine.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Amantadine.]
[C02AA05, deserpidine, Amphetamine may decrease the antihypertensive activities of Deserpidine.]
[A06AX03, lubiprostone, Amphetamine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The therapeutic efficacy of Lacosamide can be decreased when used in combination with Amphetamine.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Levodopa.]
[S02DA01, lidocaine, The metabolism of Amphetamine can be decreased when combined with Lidocaine.]
[S01AA21, amikacin, Amphetamine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The risk or severity of hypertension can be increased when Amphetamine is combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Lisuride.]
[N06AA07, lofepramine, The therapeutic efficacy of Lofepramine can be increased when used in combination with Amphetamine.]
[N05BA06, lorazepam, The therapeutic efficacy of Lorazepam can be decreased when used in combination with Amphetamine.]
[C10AA02, lovastatin, The metabolism of Amphetamine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may decrease the stimulatory activities of Amphetamine.]
[L01EG01, temsirolimus, The metabolism of Amphetamine can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Amphetamine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, The serum concentration of Amphetamine can be increased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Amphetamine can be increased when it is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Amphetamine.]
[L01BA05, pralatrexate, Amphetamine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Amphetamine may decrease the sedative and stimulatory activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Mazindol.]
[C02BB01, mecamylamine, Amphetamine may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, Amphetamine may decrease the sedative and stimulatory activities of Meclizine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Amphetamine is combined with Meclofenamic acid.]
[N05BA03, medazepam, The therapeutic efficacy of Medazepam can be decreased when used in combination with Amphetamine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, Amphetamine may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The therapeutic efficacy of Meperidine can be increased when used in combination with Amphetamine.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Mephentermine.]
[N03AB04, mephenytoin, The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Amphetamine.]
[N03AA01, mephobarbital, The serum concentration of Methylphenobarbital can be decreased when it is combined with Amphetamine.]
[N01BB03, mepivacaine, Amphetamine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[N02AX05, meptazinol, Amphetamine may increase the analgesic activities of Meptazinol.]
[G04BX16, tiopronin, Amphetamine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, Mesoridazine may decrease the stimulatory activities of Amphetamine.]
[N05AX13, paliperidone, The therapeutic efficacy of Paliperidone can be decreased when used in combination with Amphetamine.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Amphetamine is combined with Metaraminol.]
[A10BA02, metformin, Amphetamine may decrease the excretion rate of Metformin which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Dolasetron.]
[N07BC02, methadone, Amphetamine may increase the analgesic activities of Methadone.]
[N06BA03, methamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Metamfetamine.]
[A03AB07, methantheline, Amphetamine may decrease the sedative and stimulatory activities of Methantheline.]
[R06AC05, methapyrilene, Amphetamine may decrease the sedative and stimulatory activities of Methapyrilene.]
[J05AF05, lamivudine, Amphetamine may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Amphetamine.]
[S01EC05, methazolamide, Methazolamide may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[J01XX05, methenamine, The serum concentration of Amphetamine can be decreased when it is combined with Methenamine.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Amphetamine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Amphetamine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Amphetamine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, The therapeutic efficacy of Methohexital can be decreased when used in combination with Amphetamine.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Amphetamine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Methoxamine.]
[D05BA02, methoxsalen, Amphetamine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Amphetamine is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Amphetamine may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Amphetamine may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Amphetamine is combined with Methylergometrine.]
[R03DA05, aminophylline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Aminophylline.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Amphetamine is combined with Methylphenidate.]
[N03AF03, rufinamide, The therapeutic efficacy of Rufinamide can be decreased when used in combination with Amphetamine.]
[G03EK01, methyltestosterone, Amphetamine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Amphetamine is combined with Methysergide.]
[A03FA01, metoclopramide, The metabolism of Amphetamine can be decreased when combined with Metoclopramide.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The metabolism of Amphetamine can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be decreased when combined with Amphetamine.]
[V04CD01, metyrapone, Amphetamine may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Amphetamine.]
[N06AX03, mianserin, Amphetamine may decrease the sedative and stimulatory activities of Mianserin.]
[S02AA13, miconazole, The metabolism of Amphetamine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Amphetamine is combined with Aminophenazone.]
[N05CD08, midazolam, Amphetamine may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Amphetamine is combined with Midodrine.]
[G03XB01, mifepristone, The metabolism of Amphetamine can be decreased when combined with Mifepristone.]
[J05AH01, zanamivir, Amphetamine may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, Amphetamine may decrease the antihypertensive activities of Valsartan.]
[D11AX01, minoxidil, Amphetamine may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may decrease the stimulatory activities of Amphetamine.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Amphetamine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amphetamine may decrease the sedative and stimulatory activities of Amitriptyline.]
[N02AA01, morphine, Amphetamine may increase the analgesic activities of Morphine.]
[A04AA05, palonosetron, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Palonosetron.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Amphetamine can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The serum concentration of Amphetamine can be decreased when it is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Amphetamine can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, Amphetamine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be decreased when used in combination with Amphetamine.]
[G04CA04, silodosin, The therapeutic efficacy of Silodosin can be decreased when used in combination with Amphetamine.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Ipratropium.]
[N06AA17, amoxapine, Amphetamine may decrease the sedative and stimulatory activities of Amoxapine.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Amphetamine.]
[C07AA12, nadolol, The therapeutic efficacy of Nadolol can be decreased when used in combination with Amphetamine.]
[J01CA04, amoxicillin, Amphetamine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N02AF02, nalbuphine, Amphetamine may increase the analgesic activities of Nalbuphine.]
[V03AB15, naloxone, Amphetamine may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, Amphetamine may increase the analgesic activities of Naltrexone.]
[L04AC03, anakinra, The metabolism of Amphetamine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Amphetamine is combined with Naphazoline.]
[C01DA05, pentaerythritol tetranitrate, Amphetamine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Amphetamine is combined with Naproxen.]
[N06AX21, duloxetine, The metabolism of Amphetamine can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, Amphetamine may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Amphetamine.]
[S03AA01, neomycin, Amphetamine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, Amphetamine may increase the analgesic activities of Remifentanil.]
[B01AC17, tirofiban, Amphetamine may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, Amphetamine may decrease the sedative and stimulatory activities of Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[S01AA19, ampicillin, Amphetamine may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Amphetamine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Amphetamine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Amphetamine may decrease the antihypertensive activities of Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C01CE01, inamrinone, Amphetamine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Amphetamine can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypertensive activities of Amphetamine.]
[C08CA04, nicardipine, The metabolism of Amphetamine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The therapeutic efficacy of Nicergoline can be decreased when used in combination with Amphetamine.]
[N07BA01, nicotine, The metabolism of Nicotine can be decreased when combined with Amphetamine.]
[C08CA05, nifedipine, Amphetamine may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Amphetamine is combined with Niflumic acid.]
[C08CA06, nimodipine, Amphetamine may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Amphetamine may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Amphetamine.]
[C08CA08, nitrendipine, Amphetamine may decrease the antihypertensive activities of Nitrendipine.]
[R07AX01, nitric oxide, Amphetamine may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Amphetamine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The therapeutic efficacy of Zaleplon can be decreased when used in combination with Amphetamine.]
[N04BC05, pramipexole, Amphetamine may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Amphetamine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Amphetamine is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The therapeutic efficacy of Amphetamine can be increased when used in combination with Norepinephrine.]
[C02KX01, bosentan, Amphetamine may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, Amphetamine may decrease the sedative and stimulatory activities of Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Amphetamine is combined with Nylidrin.]
[L04AC04, rilonacept, The metabolism of Amphetamine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, Omeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N06AA05, opipramol, The therapeutic efficacy of Opipramol can be increased when used in combination with Amphetamine.]
[N02AA02, opium, Amphetamine may increase the analgesic activities of Opium.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Amphetamine is combined with Orciprenaline.]
[G04CA02, tamsulosin, The therapeutic efficacy of Tamsulosin can be decreased when used in combination with Amphetamine.]
[J01CF04, oxacillin, Amphetamine may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Amphetamine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, Amphetamine may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[C07AA02, oxprenolol, The therapeutic efficacy of Oxprenolol can be decreased when used in combination with Amphetamine.]
[N02AA05, oxycodone, Amphetamine may increase the analgesic activities of Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Amphetamine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Amphetamine is combined with Oxymetazoline.]
[N02AA11, oxymorphone, Amphetamine may increase the analgesic activities of Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may decrease the stimulatory activities of Amphetamine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Amphetamine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Oxyphenonium.]
[N05AH05, asenapine, Amphetamine may decrease the sedative and stimulatory activities of Asenapine.]
[N02AX06, tapentadol, Amphetamine may increase the analgesic activities of Tapentadol.]
[M03AC01, pancuronium, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Pancuronium.]
[J04AB30, capreomycin, Amphetamine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[N05CC05, paraldehyde, The therapeutic efficacy of Paraldehyde can be decreased when used in combination with Amphetamine.]
[C02KC01, pargyline, Pargyline may increase the hypertensive activities of Amphetamine.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[G04BD11, fesoterodine, Amphetamine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The therapeutic efficacy of Penbutolol can be decreased when used in combination with Amphetamine.]
[N05AG03, penfluridol, Penfluridol may decrease the stimulatory activities of Amphetamine.]
[J01CE09, penicillin G procaine, Amphetamine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, Amphetamine may increase the analgesic activities of Pentazocine.]
[N05CA01, pentobarbital, The therapeutic efficacy of Pentobarbital can be decreased when used in combination with Amphetamine.]
[L01XX08, pentostatin, Amphetamine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Pentoxifylline.]
[N05AB10, perazine, Perazine may decrease the stimulatory activities of Amphetamine.]
[N04BC02, pergolide, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Pergolide.]
[C08EX02, perhexiline, The metabolism of Amphetamine can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, Perphenazine may decrease the stimulatory activities of Amphetamine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Amphetamine.]
[N02AD02, phenazocine, Amphetamine may increase the analgesic activities of Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the hypertensive activities of Amphetamine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Amphetamine.]
[R06AB05, pheniramine, Amphetamine may decrease the sedative and stimulatory activities of Pheniramine.]
[N03AA02, phenobarbital, The serum concentration of Phenobarbital can be decreased when it is combined with Amphetamine.]
[N01AH04, phenoperidine, Amphetamine may increase the analgesic activities of Phenoperidine.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Amphetamine.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Phentermine.]
[V03AB36, phentolamine, The therapeutic efficacy of Phentolamine can be decreased when used in combination with Amphetamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Amphetamine is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Amphetamine is combined with Phenylephrine.]
[A02BC06, dexlansoprazole, Dexlansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The therapeutic efficacy of Phenytoin can be decreased when used in combination with Amphetamine.]
[L04AB06, golimumab, The metabolism of Amphetamine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Amphetamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Amphetamine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[C08CX01, mibefradil, The metabolism of Amphetamine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The therapeutic efficacy of Amphetamine can be decreased when used in combination with Pimozide.]
[C07AA03, pindolol, The therapeutic efficacy of Pindolol can be decreased when used in combination with Amphetamine.]
[J01CA12, piperacillin, Amphetamine may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Amphetamine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Amphetamine.]
[N05AC04, pipothiazine, Pipotiazine may decrease the stimulatory activities of Amphetamine.]
[N06BX03, piracetam, Amphetamine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Amphetamine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Pirenzepine.]
[N02AC03, pirinitramide, Amphetamine may increase the analgesic activities of Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Amphetamine is combined with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Amphetamine which could result in a higher serum level.]
[N02CX01, pizotyline, Amphetamine may decrease the sedative and stimulatory activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Amphetamine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Amphetamine may decrease the antihypertensive activities of Irbesartan.]
[A10BG02, rosiglitazone, Amphetamine may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[L04AC08, canakinumab, The metabolism of Amphetamine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The metabolism of Amphetamine can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, Amphetamine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Amphetamine may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[V03AB21, potassium iodide, The risk or severity of adverse effects can be increased when Amphetamine is combined with Potassium Iodide.]
[C07AB01, practolol, The therapeutic efficacy of Practolol can be decreased when used in combination with Amphetamine.]
[C02CA01, prazosin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Amphetamine.]
[H02AB07, prednisone, Amphetamine may decrease the excretion rate of Prednisone which could result in a higher serum level.]
[R06AX05, antazoline, Amphetamine may decrease the sedative and stimulatory activities of Antazoline.]
[P01BA03, primaquine, The metabolism of Amphetamine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The serum concentration of Primidone can be decreased when it is combined with Amphetamine.]
[M04AB01, probenecid, Amphetamine may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Amphetamine.]
[S01HA05, procaine, Procaine may increase the hypertensive activities of Amphetamine.]
[L01XB01, procarbazine, Procarbazine may increase the hypertensive activities of Amphetamine.]
[C10AB05, fenofibrate, Amphetamine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, Prochlorperazine may decrease the stimulatory activities of Amphetamine.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Amphetamine.]
[N05AA03, promazine, Amphetamine may decrease the sedative and stimulatory activities of Promazine.]
[R06AD02, promethazine, Amphetamine may decrease the sedative and stimulatory activities of Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Propafenone can be decreased when used in combination with Amphetamine.]
[A03AB05, propantheline, Amphetamine may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[R06AX26, fexofenadine, Amphetamine may decrease the sedative and stimulatory activities of Fexofenadine.]
[N05AC01, periciazine, The therapeutic efficacy of Periciazine can be decreased when used in combination with Amphetamine.]
[N05CM06, propiomazine, Amphetamine may decrease the sedative and stimulatory activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of hypertension can be increased when Amphetamine is combined with Propofol.]
[N02AC04, propoxyphene, Amphetamine may increase the analgesic activities of Dextropropoxyphene.]
[C07AA05, propranolol, The therapeutic efficacy of Propranolol can be decreased when used in combination with Amphetamine.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Amphetamine is combined with Propylthiouracil.]
[N02CC04, rizatriptan, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Rizatriptan.]
[B01AC09, epoprostenol, Amphetamine may decrease the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Amphetamine.]
[N06AA11, protriptyline, The therapeutic efficacy of Protriptyline can be increased when used in combination with Amphetamine.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, Amphetamine may decrease the sedative and stimulatory activities of Aripiprazole.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Amphetamine is combined with Dalfampridine.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Methscopolamine.]
[P02CC01, pyrantel, Amphetamine may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Amphetamine may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[R06AC01, pyrilamine, Amphetamine may decrease the sedative and stimulatory activities of Mepyramine.]
[C01BA01, quinidine, The therapeutic efficacy of Quinidine can be decreased when used in combination with Amphetamine.]
[P01BC01, quinine, The metabolism of Amphetamine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, Amphetamine may decrease the sedative and stimulatory activities of Ranitidine.]
[C02AA01, rescinnamine, Amphetamine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The serum concentration of Amphetamine can be decreased when it is combined with Reserpine.]
[J05AP01, ribavirin, Amphetamine may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Amphetamine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Amphetamine is combined with Ritodrine.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Amphetamine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Amphetamine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Amphetamine is combined with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Scopolamine.]
[N05CA06, secobarbital, The therapeutic efficacy of Secobarbital can be decreased when used in combination with Amphetamine.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Amphetamine is combined with Selegiline.]
[J01GB08, sisomicin, Amphetamine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Amphetamine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Amphetamine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The therapeutic efficacy of Sotalol can be decreased when used in combination with Amphetamine.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AF01, isocarboxazid, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N06AF03, phenelzine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[L01XB01, procarbazine, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
[N04BD01, selegiline, Amphetamine and derivatives - monoamine oxidase (MAO) inhibitors]
